BioTherapeutics Inc.

Official @BioTherap site for Health News and Precision Medicine Innovation #PrecisionMedicine #Informatics #AI #MachineLearning #PredictiveAnalytics #Modeling

[BioTherapeutics Inc. @BioTherap]

At #IMMUNOLOGY2026 we shared new data on omilancor, an oral, once-daily gut-restricted LANCL2 medicine—showing strong efficacy signals in IBD, recurrent C. difficile infection model and concomitant CDI and IBD. Read the article: https://t.co/KpZbmOyqIX

[NImmune Biopharma @NImmuneBio]

Listen to our Founder & CEO, Dr. Josep Bassaganya-Riera, on the @BioWorld Insider podcast, where he discusses how NImmune is leveraging the TITAN-X AI platform to advance precision medicine in inflammatory and autoimmune diseases. Listen here: https://t.co/orjHldf0K6

[NImmune Biopharma @NImmuneBio]

Today on #WorldIBDDay, we stand with the global IBD community in the fight against Crohn’s disease and ulcerative colitis. At NImmune, our team is advancing omilancor, a first-in-class oral therapeutic targeting LANCL2, now in Phase 3.

[NImmune Biopharma @NImmuneBio]

New #DDW2025 data: once-daily oral omilancor outperformed anti-TL1A in IBD on efficacy & safety. Results show reversal of Treg depletion & mitochondrial dysfunction in UC. Best-in-class profile supports NDA path by 2027. Read more: https://t.co/gVLv60HhoR

[The NIMML Institute @NIMMLab]

New data presented at #DDW2025 shows LANCL2 activation via omilancor outperforms anti-TL1A in IBD. Backed by our TITAN-X A.I. platform, results show superior efficacy, unmatched safety, and reversal of Treg/mitochondrial dysfunction in UC. Read more: https://t.co/nfJH1mSxeY

[NImmune Biopharma @NImmuneBio]

Thrilled to share that our Founder & CEO, Dr. Josep Bassaganya-Riera, was featured on @LaunchBio’s NextGen VC podcast to discuss his journey building Landos Biopharma from new scientific findings to a $600M market cap company. Listen here: https://t.co/uYI1JVPSvV

[NImmune Biopharma @NImmuneBio]

Thrilled to see @NIMMLab’s new #TITANX applications in @AnnualReviews. This #AI platform is driving our drug pipeline, from omilancor to NIM-1324, accelerating #PrecisionMedicine for #immunology. Keep innovating!

[The NIMML Institute @NIMMLab]

Excited to share new case studies in @AnnualReviews showing how our TITAN-X #AI platform fuels next-gen #immunology & #inflammation therapies. By unlocking novel targets like LANCL2, we’re advancing #PrecisionMedicine. Read the peer-reviewed article here: https://t.co/eQ9DXsRwOl

[NImmune Biopharma @NImmuneBio]

Check out our Founder & CEO, Dr. Josep Bassaganya-Riera, on the Life Science & Biotech CEO Stories podcast as he shares his success story and how he's leading the charge in applying A.I. to biotech innovation. Listen here: https://t.co/uEugnyXVBv

[NImmune Biopharma @NImmuneBio]

Our Founder and CEO, Dr. Bassaganya-Riera, recently edited a collection of articles for @FrontiersIn Immunology on new computational modeling methods to study alloimmune T-cell responses. Read the full editorial here: https://t.co/ZVrHBSIhp0 #BioPharma

[The NIMML Institute @NIMMLab]

We are pleased to announce that new data from two IBD studies will be presented at @DDWMeeting. The studies focus on the best-in-class efficacy and safety, novel mechanism and combination therapies of omilancor & TL1A. Read more: https://t.co/EpeRpUUruF

[NImmune Biopharma @NImmuneBio]

We are pleased to announce that new data from two IBD studies will be presented at @DDWMeeting. The studies focus on the best-in-class efficacy and safety profile, novel mechanism and combination therapies of omilancor & TL1A. Read more: https://t.co/E2023TCRpR

[NImmune Biopharma @NImmuneBio]

Excited to share publication of positive Phase 1 results for NIM-1324 in treating Systemic Lupus Erythematosus! This milestone highlights our commitment to precision medicine and addressing unmet needs in immune-mediated diseases. Kudos to @NIMMLab for the collaboration!

[The NIMML Institute @NIMMLab]

Our paper on Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, was accepted to the #CTSJournal! Findings validated NIM-1324 as a well-tolerated treatment for SLE. Read it in @ASCPTjournals: https://t.co/Y1F6Vcir7O

[NImmune Biopharma @NImmuneBio]

We are pleased to share that NImmune will be attending #JPM2025 in San Francisco from January 13–16! We look forward to engaging in impactful conversations, connecting with industry leaders, and building our network to start 2025 on a strong note.

[The NIMML Institute @NIMMLab]

A recent study from researchers at @CUNYNeuro finds promising new therapeutic potential in the treatment of Alzheimer’s disease for LANCL2 drugs, further validating our TITAN-X precision medicine platform in new indication. Read the full paper here: https://t.co/crh4jOhyrg

[NImmune Biopharma @NImmuneBio]

A recent study from researchers at @CUNYNeuro identified LANCL2 as a new therapeutic target for Alzheimer’s disease and demonstrates the therapeutic efficacy of omilancor in a rat model. Read the full paper in @biorxivpreprint: https://t.co/p7GwxWofBk

[BioTherapeutics Inc. @BioTherap]

Thrilled our sister company @NImmuneBio is featured in Valley Business FRONT! As part of Virginia’s BioHealth Innovation ecosystem, we’re proud of their groundbreaking immunology R&D. Together with Dr. Bassaganya-Riera, we’re pushing biotech boundaries. Congrats, NImmune team!

[NImmune Biopharma @NImmuneBio]

Excited to be featured in Valley Business FRONT! Our CEO Dr. Bassaganya-Riera discusses Nimmune’s role in Virginia’s BioHealth innovation ecosystem. We’re pushing boundaries in immunology with AI-driven drug development and transformative clinical trials. https://t.co/ePibmGVbwP

[NImmune Biopharma @NImmuneBio]

On Oct. 21, we acquired development and commercialization rights for omilancor in Greater China. We now wholly own global rights to omilancor, the best-in-class therapy for ulcerative colitis and other I&I indications. Read the full announcement: https://t.co/PQCEBD8DEh

[NImmune Biopharma @NImmuneBio]

Research published in @J_Immunol validates NIM-1324 as the first LANCL2 agonist effective in systemic inflammation across 3 in vivo lupus models. Read more about how @NIMMLab is making groundbreaking mechanistic discoveries: https://t.co/a2iunZwow1